Lifeboat Foundation

A new publication by an international team of scientists has proposed a new healthcare framework to help older people stay healthier for longer by improving the development of therapies that target age-related diseases.

Society is aging, and we need to change healthcare for the better

This new publication urges World Health Organization (WHO), governments, and the medical science community to work together and develop classifications and staging systems using a new framework as a basis for diagnosing and treating age-related diseases.

A Kansas-based company launched a clinical trial in Colombia to reverse aging. But will it work?

The unproven gene therapy aims to lengthen a person’s telomeres.

DNA damage, which results in genomic instability, is one of the primary hallmarks of aging. Today, we want to highlight an recent open access review that explores the DNA damage response during aging.

The role of DNA damage

Some researchers have long suggested that damage to our DNA is a major reason why we age and a strong determinant of species longevity; indeed, many-long lived species have extremely stable genomes, such as bristlecone pines, which have lifespans of over 5000 years.

A new open access paper takes a look at tryptophan and the role that it plays in the dysfunction of the immune system in the context of the age-related changes that occur in the microbiome [1].

The microbiome

The gut microbiome is a complex ecosystem of bacteria, archaea, eukarya, and viruses that live inside of us, some beneficial and some harmful, the balance of which keeps us alive. Four microbial phyla, Firmicutes, Bacteroides, Proteobacteria, and Actinobacteria, make up 98% of the total population of the intestinal microbiome.

Accelerating rejuvenation therapies to repair the damage of aging. Berlin, May 21 — 23.

In mouse models of Alzheimer’s disease, the investigational drug candidates known as CMS121 and J147 improve memory and slow the degeneration of brain cells. Now, Salk researchers have shown how these compounds can also slow aging in healthy older mice, blocking the damage to brain cells that normally occurs during aging and restoring the levels of specific molecules to those seen in younger brains.

The research, published last month in the journal eLife, suggests that the drug candidates may be useful for treating a broader array of conditions and points out a new pathway that links normal aging to Alzheimer’s disease.

“This study further validated these two compounds not only as Alzheimer’s drug candidates but also as potentially more widely useful for their anti-aging effects,” says Pamela Maher, a senior staff scientist at Salk and a co-corresponding author of the new paper.

NaNotics, in another breakthrough, is promising a new kind of medication, and suggests to have found a way to combat age related diseases; boldly going where no nanotech has gone before.

Lou Hawthorne of NaNotics, LLC opened his presentation at a recent longevity investor event using a clip from Star Trek that shows captain Kirk being giving a shot that restores him to his younger years.

“It’s tempting to assume it’s a drug, but what if the content of that syringe was something new?” NaNotics’ CEO Hawthorne asked. “NaNots are a new class of medicine. They are engineered to do just one thing and that’s the holy grail of medicine design, because most drugs do two things: something you want them to do, and something you don’t. In other words, side effects.”

Excerpt of Brent Nally’s interview to Dr. Michael Fossel about his company Telocyte and telomerase gene therapy. The interview took place on November 16, 2019.

To watch the entire three and a half hour enlightening interview click here:

Continue reading “Michael Fossel on activating Telomerase as best single antiaging intervention” »